Đánh giá đáp ứng điều trị với Entecavir ở bệnh nhân viêm gan vi rút B mạn tính hoạt động có HBeAg dương tính và âm tính

Research on 70 patients with chronic hepatitis B (45 patients with HBeAg(+) and 25 patients with H BeAg (-)) at the AS Department of 103 Hospital and Department of Infectious Diseases of Dong Da General Hospital in Hanoi from 01/2013 - 07/2014 showed that functional symptoms such as fatigue, loss of appetite, pain in the liver area before treatment account 74.29 percent, 50 percent, 32.86 percent; physical symptoms including jaundice and hepatomegaly up only 21.43 percent, with no difference in ALT, total bilirubin in the blood in two groups. HBV - DNA concentrations average among HBeAg(+) group was 7.13 +/- 1.07, higher than that of HBeAg(-) group was 6.32 +/- 1.28 (p 0.001). The clinical symptoms after 48 weeks of treatment significantly reduced, the rate normalization of liver enzymes and high blood bilirubin levels after 12 and 48 weeks, there is no difference between the 2 groups. The rate achieved HBV - DNA levels below the level of detection after 12 weeks among HBeAg(-) higher compared with HBeAg(+) (p 0.05). The rate of HBeAg eroconversion after 12, 24 and 48 weeks of treatment reached 15.55 percent, 22.22 percent and 29.26 percent. After 48 weeks, with 26.83 percent of the patients in HBeAg(+) group, 84 percent patients in HBeAg(-)group achieved complete response.